Evidence map›Paper›PMID 28550464›Full record

ArticleJournal of endocrinological investigation2017

Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study.

M Albertelli, E Nazzari, S Sciallero, F Grillo, S Morbelli, F De Cian, G Cittadini, E Ambrosetti, A Ciarmiello, D Ferone and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

M AlbertelliEndocrinology Unit, Department of Internal Medicine (DiMI), University of Genova, Genoa, Italy.
E NazzariEndocrinology Unit, Department of Internal Medicine (DiMI), University of Genova, Genoa, Italy.
S ScialleroMedical Oncology Unit, IRCCS Policlinico San Martino, Genoa, Italy.
F GrilloPathology unit, Department of Health Science (DiSSAL), University of Genova, Genoa, Italy.
S MorbelliNuclear Medicine Unit, Department of Health Science (DiSSAL), University of Genova, Genoa, Italy.
F De CianOncologic Surgery Unit, Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genova, Genoa, Italy.
G CittadiniDepartment of Radiology, IRCCS Policlinico San Martino, Genoa, Italy.
E AmbrosettiEndocrinology Unit, Department of Internal Medicine (DiMI), University of Genova, Genoa, Italy.
A CiarmielloDepartment of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy.
D FeroneEndocrinology Unit, Department of Internal Medicine (DiMI), University of Genova, Genoa, Italy. ferone@unige.it.
IRCCS Policlinico San Martino, University of Genova Neuroendocrine Tumor Board
University of Genoa · ITOspedale Policlinico San Martino · ITCTO Andrea Alesini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Octreotide and lanreotide, the first-generation somatostatin analogs, successfully control hormone hyperproduction, and related syndromes, in patients with acromegaly and neuroendocrine tumors. However, their anti-tumor effect, rather evident in large number of pituitary adenomas in acromegalic patients, has been hypothesized for a long time in patients with neuroendocrine tumors as well, although a significant tumor shrinkage has rarely been observed. However, the recent publication of the CLARINET study has strengthened the evidence, already emerged with the PROMID trial, that the long-term treatment with the first-generation long-acting somatostatin analogs may exert an anti-tumor activity on G1 and G2 enteropancreatic neuroendocrine tumors, as well. After the publication, majority of international guidelines have updated their algorithms in line with these results and this class of drugs obtained the indication as anti-tumor agents in the majority of patients with neuroendocrine tumors.

Indexed as

Antineoplastic AgentsClinical Trials as TopicHumansNeuroendocrine TumorsSomatostatinAntineoplastic AgentsSomatostatinAnti-tumor effectClinical trialLanreotideNeuroendocrine tumorsOctreotideSomatostatin analogs

Identifiers

PMID28550464
OpenAlexW2619085378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.